tetano
Editor, Senior Moderator
J Pharm Sci. 2011 Dec 20. doi: 10.1002/jps.23019. [Epub ahead of print]
Dissolvable microneedle patches for the delivery of cell-culture-derived influenza vaccine antigens.
Kommareddy S, Baudner BC, Oh S, Kwon SY, Singh M, O'hagan DT.
Source
Vaccines Research, Novartis Vaccines, Cambridge, Massachusetts. sushma.kommareddy@novartis.com.
Abstract
Microneedle patches are gaining increasing attention as an alternative approach for the delivery of vaccines. In this study, a licensed seasonal influenza vaccine from 2007 to 2008 was fabricated into dissolvable microneedles using TheraJect's microneedle technology (VaxMat). The tips of the microneedles were made of antigens mixed with trehalose and sodium carboxymethyl cellulose. The patches containing 15 μg per strain of the influenza antigen were characterized extensively to confirm the stability of the antigen following fabrication into microneedles. The presence of excipients and very low concentrations of the vaccine on the microneedle patches made it challenging to characterize using the conventional single radial immunodiffusion analysis. Novel techniques such as capture enzyme-linked immunosorbent assay and enzyme digestion followed by mass spectroscopy were used to characterize the antigens on the microneedle patches. The in vivo studies in mice upon microneedle administration show immunogenicity against monovalent H1N1 at doses 0.1 and 1 μg and trivalent vaccine at a dose of 1 μg. The initial data from the mouse studies is promising and indicates the potential use of microneedle technology for the delivery of influenza vaccine. ? 2011 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci.
Copyright ? 2011 Wiley Periodicals, Inc.
PMID:
22190403
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/22190403
Dissolvable microneedle patches for the delivery of cell-culture-derived influenza vaccine antigens.
Kommareddy S, Baudner BC, Oh S, Kwon SY, Singh M, O'hagan DT.
Source
Vaccines Research, Novartis Vaccines, Cambridge, Massachusetts. sushma.kommareddy@novartis.com.
Abstract
Microneedle patches are gaining increasing attention as an alternative approach for the delivery of vaccines. In this study, a licensed seasonal influenza vaccine from 2007 to 2008 was fabricated into dissolvable microneedles using TheraJect's microneedle technology (VaxMat). The tips of the microneedles were made of antigens mixed with trehalose and sodium carboxymethyl cellulose. The patches containing 15 μg per strain of the influenza antigen were characterized extensively to confirm the stability of the antigen following fabrication into microneedles. The presence of excipients and very low concentrations of the vaccine on the microneedle patches made it challenging to characterize using the conventional single radial immunodiffusion analysis. Novel techniques such as capture enzyme-linked immunosorbent assay and enzyme digestion followed by mass spectroscopy were used to characterize the antigens on the microneedle patches. The in vivo studies in mice upon microneedle administration show immunogenicity against monovalent H1N1 at doses 0.1 and 1 μg and trivalent vaccine at a dose of 1 μg. The initial data from the mouse studies is promising and indicates the potential use of microneedle technology for the delivery of influenza vaccine. ? 2011 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci.
Copyright ? 2011 Wiley Periodicals, Inc.
PMID:
22190403
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/22190403